
Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

